Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
One year after the occurrence of the first case of infection by the Middle East Respiratory Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to propose. The World Health Organization, as well as several other national agencies, are still working on different clinical...
Guardado en:
Autores principales: | Emmanuel Faure, Julien Poissy, Anne Goffard, Clement Fournier, Eric Kipnis, Marie Titecat, Perinne Bortolotti, Laura Martinez, Sylvain Dubucquoi, Rodrigue Dessein, Philippe Gosset, Daniel Mathieu, Benoit Guery |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/be195de134d24f908da6e1ca896ecf3b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
por: Zatsepin TS, et al.
Publicado: (2016) -
Oncolytic Virotherapy: From Bench to Bedside
por: Ludi Yang, et al.
Publicado: (2021) -
Inflammation, Bone Healing and Osteonecrosis: From Bedside to Bench
por: Goodman SB, et al.
Publicado: (2020) -
Clinical utility of asthma biomarkers: from bench to bedside
por: Vijverberg SJH, et al.
Publicado: (2013) -
Antineutrophil cytoplasmic antibodies-associated glomerulonephritis: From bench to bedside
por: Yong-Xi Chen, et al.
Publicado: (2018)